IsKezar Life Sciences (KZR) An Attractive Buy? William Blair Initiates Coverage

July 16, 2018 - By Billy Entrekin

How William Blair Currently Rates Kezar Life Sciences (KZR)

In an analyst note shared with investors on 16 July, equity analysts at William Blair initiated coverage on Kezar Life Sciences (KZR) shares. The financial company issued a key Outperform rating for KZR stock.

The stock increased 0.76% or $0.12 during the last trading session, reaching $15.92. About 60,295 shares traded. Kezar Life Sciences, Inc. (KZR) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. The company has market cap of $303.62 million.

More notable recent Kezar Life Sciences, Inc. (NASDAQ:KZR) news were published by: Bizjournals.com which released: “Pair of upsized Bay Area biotech IPOs head in opposite directions after raising $335M” on June 28, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” published on June 21, 2018, Prnewswire.com published: “Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to …” on June 25, 2018. More interesting news about Kezar Life Sciences, Inc. (NASDAQ:KZR) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on July 16, 2018 as well as Bizjournals.com‘s news article titled: “Another Peninsula biotech seeks big IPO payday” with publication date: June 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.